Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (109)
  3. Review (18)
  4. Research Letter (14)
  5. Editorial (6)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (371)
  2. Center for Hematologic Malignancies (371)
  3. Department of Medicine (371)
  4. Hematologic Malignancies, Division of (371)
  5. Hematology-Oncology Fellows (111)
  6. GSK Faculty (92)

More Groups

People
  1. Martin Tallman (118)
  2. Ross Levine (75)
  3. Aaron Goldberg (43)
  4. Andriy Derkach (33)
  5. Jan Bewersdorf (33)
  6. Christopher Famulare (31)

More People

Years
  1. 2025 (20)
  2. 2024 (45)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (171)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (18)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (186)
  2. Elsevier Inc. (32)
  3. American Society of Clinical Oncology (28)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enasidenib is highly active in previously untreated IDH2 mutant AML: Early results from the Beat AML Master Trial
    Meeting Abstract

    Stein, E. M.; Shoben, A.; Borate, U.; Baer, M. R.; Stock, W.; Patel, P. A.; Kovacsovics, T.; Blum, W.; Vergilio, J. A.; Heerema, N. A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: Results from a phase 1 dose escalation and expansion study
    Meeting Abstract

    Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W. B.; Erba, H. P.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: Initial results of a phase II study
    Meeting Abstract

    Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; Stein, E. M.; Kadia, T. M.; Mauro, M. J.; Pemmaraju, N.; Alvarez, K.; Ard, N.; Goodman, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A precision medicine heirarchical classification developed using variant allele frequency (VAF) for treatment of older patients (Pts) with acute myeloid leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) historical patient control
    Meeting Abstract

    Mims, A. S.; Kohlschmidt, J.; Borate, U.; Norris, B.; Bucy, T.; Blachly, J. S.; Orwick, S.; Eisfeld, A. K.; Papaioannou, D.; Nicolet, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: Results from a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Foran, J. M.; Stone, R. M.; Patel, P. A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Early results from a biomarker-directed phase 2 trial of SY-1425 in combination with azacitidine or daratumumab in non-APL acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Meeting Abstract

    Cook, R. J.; Moyo, T.; Liesveld, J. L.; Rizzieri, D. A.; Stein, E. M.; De Botton, S.; Roboz, G. J.; Sekeres, M. A.; Jurcic, J. G.; Raza, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial report of the beat AML umbrella study for previously untreated AML: Evidence of feasibility and early success in molecularly driven phase 1 and 2 studies
    Meeting Abstract

    Burd, A.; Levine, R. L.; Shoben, A.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M. W.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • AML with mutations in IDH1 and DNMT3A exhibits a distinct epigenetic signature with poorer overall survival
    Meeting Abstract

    Ahr, K.; Famulare, C.; Koche, R.; Spitzer, B.; Levine, R. L.; Tallman, M. S.; Goldberg, A. D.; Stein, E. M.; Glass, J. L.
    Blood (2018)

    Fulltext@MSK | Save
  • Emerging real-world midostaurin treatment patterns and outcomes in FLT3-mutated acute myeloid leukemia at a comprehensive cancer center
    Meeting Abstract

    Willis, C.; Menon, J.; Unni, S.; Au, T.; Ndife, B.; Joseph, G. J.; Bonifacio, G. J.; Stein, E. M.; Tantravahi, S. K.; Shami, P. J.; more...
    Blood (2018)

    Fulltext@MSK | Save